Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir in Kidney Transplant Donors to Reduce Viral Transmission
NCT01329185Phase 2Completed
- Sponsor
- University of Minnesota
- Start
- Jun 2011
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valganciclovir in cytomegalovirus infection (CMV), Epstein-Barr virus infection, sponsored by University of Minnesota. Started Jun 2011; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT01329185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01329185.